VAULT Men's Health Review: 1,454 Pages, Ten Peptides, and a Supplement Disclaimer

"Exclusively 503B"

The second contradiction is the one that decides this review's outbound policy.

From the FAQ:

All VAULT peptides are sourced exclusively from US-licensed 503B compounding pharmacies. These facilities are FDA-registered and follow strict cGMP (current Good Manufacturing Practice) standards.

From the about page, three more times: "503B Pharmacy Partners", "US-Licensed 503B Facilities", "Compounds sourced only from FDA-registered 503B compounding pharmacies."

Section 503B of the Act describes an outsourcing facility: a compounder that elects to register with FDA, submits to FDA inspection and to CGMP, and may make drugs in batches without a prescription for a named patient. ¹⁵ Registration is not approval; FDA licenses no pharmacy; and "US-licensed 503B" is a phrase that fuses a state function and a federal one into a status that does not exist.

The FAQ's own explanation gets the section backwards:

Others are prescribed as compounded medications under the FDA's compounding framework (Section 503B), which allows licensed pharmacies to compound medications that are not commercially available when prescribed by a physician.

That describes 503A — patient-specific compounding by a state-licensed pharmacy. Batch production without a patient-specific prescription is the defining feature of the section being cited. 503A and 503B are not two words for the same thing.

But the decisive part is what an outsourcing facility may compound from. Under 503B a bulk drug substance must appear on FDA's 503B bulks list or on the drug-shortage list. Now read VAULT's menu against FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks", content current as of 22 April 2026: ¹

Six of the ten products. FDA's stated reasons include, for BPC-157, that compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration"; for AOD-9604, that they "may pose significant risk for immunogenicity"; and, for several, that the agency has identified no human exposure data at all.

So "sourced exclusively from 503B pharmacies" and "BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, AOD-9604" describe two different supply chains, and only one of them can be the real one. The FAQ elsewhere asserts that VAULT's physicians "only prescribe peptides that can be legally compounded" and "stay current on all regulatory changes".

AOD-9604: a price, a dose, a duration and an empty registry

Of the ten products, one shows the shape most cleanly.

AOD-9604 — Modified fragment of growth hormone that specifically targets fat metabolism without affecting blood sugar or growth.

Key Benefits: Targeted fat loss · Preserved muscle mass · Enhanced metabolism · No blood sugar impact · Improved body composition · Safe fat burning

Dosage: 250-300 mcg subcutaneously daily · Duration: 12-16 weeks for optimal results

Possible Side Effects: Injection site reactions · Very rare: temporary fatigue · Excellent safety profile

Starting at $199/mo

A ClinicalTrials.gov v2 intervention search for "AOD-9604" on 9 August 2026 returned zero studies. ¹⁰ Not few. None — no phase 1, no phase 2, nothing, for any indication, anywhere in the registry. DailyMed returns no label containing it.

Six benefit claims, two safety claims, a daily dose and a sixteen-week course, with nothing registered behind any of them. When a claim outruns its evidence, this is the far end of the range.

Selling the same molecule twice

In the Healing & Recovery category, two products sit next to each other:

TB-500 is the 17-23 fragment — seven amino acids. Thymosin beta-4 is the whole 43-amino-acid protein. The registry keeps them apart: the only registered TB-500 study is titled "TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers", phase 1/2, recruiting, target 80. ⁵

The full protein has considerably more behind it — and none of it is an injection. ReGenTree ran two completed phase 3 trials of RGN-259, thymosin beta-4 as an ophthalmic solution, enrolling 601 and 700 participants. ^{6 7} RegeneRx's phase 2 work was topical, in pressure ulcers and venous stasis ulcers. ⁸ The one registered study of an injectable preparation, NCT01311518, was withdrawn with zero enrolment. ⁹

So the strongest evidence in VAULT's entire catalogue belongs to an eye drop, and it is attached to a subcutaneous injection sold for "improved flexibility" at $379 a month. Route changes the drug, and here it changes it twice over.

PT-141, on a men's health site

PT-141 — Melanocortin receptor agonist that enhances sexual arousal and function through central nervous system pathways.

Key Benefits: Enhanced libido · Improved erectile function · Increased sexual arousal · Better sexual satisfaction · Works in both men and women · Non-vascular mechanism

The mechanism is right, and unusual: bremelanotide acts on melanocortin-4 receptors in the hypothalamus rather than on blood vessels, which genuinely distinguishes it from the PDE5 inhibitors.

The evidence is real too — and it is somebody else's. VYLEESI (bremelanotide) injection holds a current FDA label. ¹¹ The two phase 3 trials that produced it, NCT02333071 and NCT02338960, randomised 723 and 714 premenopausal women with hypoactive sexual desire disorder. ^{12 13} The phase 2 that preceded them enrolled 612 premenopausal women. ¹⁴

"Improved erectile function" was not an endpoint, because there were no men in the trials. On a platform called VAULT Men's Health, that is the population swap pointed directly at the audience.

What the FAQ says about the evidence

Three claims in the FAQ are checkable in one query each.

BPC-157 has over 100 published research papers demonstrating healing properties.

A PubMed search for BPC-157 or "BPC 157" in title or abstract, restricted to the randomised-controlled-trial publication type, returns zero records. ² There are indeed many papers; they are animal and in-vitro work, which is what VAULT's own product page says in its first sentence and stops saying immediately afterwards. Two studies are registered: a phase 1 pilot whose status has read UNKNOWN since a listed completion of March 2016 ³, and a phase 2 in hamstring strain that began recruiting on 2 February 2026 and reports in 2028. ⁴ The distance between what people report about healing peptides and what has been trialled is the whole subject.

CJC-1295 and Ipamorelin have substantial clinical evidence for growth hormone optimization.

CJC-1295 has exactly one registered trial in the world — NCT00267527, phase 2, in HIV patients with visceral obesity — and it was terminated in 2006. Ipamorelin's two completed phase 2 trials, both sponsored by Helsinn, studied post-operative ileus and gastrointestinal recovery. Neither molecule has a registered body-composition outcome.

Post-COVID legislation (the Ryan Haight Act exemptions and state telehealth parity laws) has firmly established telehealth as a legitimate avenue for medical consultations and prescribing.

The Ryan Haight Online Pharmacy Consumer Protection Act governs the online prescribing of controlled substances. None of these ten peptides is a controlled substance. The statute cited has no application to any prescription this platform issues.

Nobody is named

Two absences, stated exactly.

No pharmacy. Across 1,454 pages the supply chain is described only as "US-licensed 503B compounding pharmacies", "our pharmacy partners" and "licensed pharmacies". Not one company, address or licence number.

No physician. The about page describes a "Medical Advisory Board" by role — "Board-Certified Physicians", "Clinical Pharmacists", "Research Advisors" — and then explains:

Individual physician identities are available upon request during your consultation for patient privacy and security.

Patient privacy protects the patient. It has never been a reason to withhold the name of the person writing the prescription. A prospective customer is asked to accept a physician-supervised protocol from a physician who will be identified after the consultation begins.

Why this review carries no link

This site declines to route readers to a provider whose own published statements cannot all be true at once. Three pairs qualify here:

1. 1 — Current step

   "Not intended to treat any disease" vs 935 condition pages

   Both live, both published, mutually exclusive.

2. 2 — Current step

   "Exclusively 503B" vs six FDA-flagged bulk substances

   An outsourcing facility may not compound from substances that are on neither the 503B bulks list nor the shortage list.

3. 3 — Current step

   "Money-back guarantee" vs "case-by-case"

   The FAQ promises a 30-day refund; the Terms of Service say refunds are handled case by case.

That is a documentation finding, not a safety finding, and nothing above says anyone has been harmed. It is also reversible: name the pharmacy, state the correct regulatory category for each product, take the supplement disclaimer off a prescription platform, and make the two refund documents agree, and the position should be looked at again.

Until then, the most useful thing this page can do is print what the company printed, and leave the reader with a name they can check rather than a link they can click.